TEM Tempus AI, Inc.
Company Analysis
Latest News
🟢 Tempus AI, Inc. trades 4.5% higher on analyst upgrade and AI sector rebound
Tempus AI, Inc. is trading 4.5% up today at $51.03, driven by a positive analyst rating and a broader recovery in AI-related stocks following recent market...
🟢 Tempus AI, Inc. is trading 4.6% up today as it rebounds from recent volatility
Tempus AI, Inc. is trading 4.6% up at $51.04, rebounding from recent volatility following a week of sharp swings between gains and losses. • The stock appears...
🔴 Tempus AI, Inc. is trading 5.4% down today as the Nasdaq drops over 2% in a broader tech selloff
Tempus AI, Inc. is trading 5.4% down at $45.97 as growth and AI-focused stocks weaken in tandem with a sharp decline in the Nasdaq Composite. • The move...
🔴 Tempus AI, Inc. is trading 4.6% down today amid a broader tech and AI sector selloff
Tempus AI, Inc. is trading 4.6% down today at $46.34, tracking a wider retreat in technology and artificial intelligence equities as market sentiment...
🟢 Tempus AI, Inc. is trading 4.2% up today as growth stocks rebound from last week's selloff
Tempus AI, Inc. is trading 4.2% up today at $48.39 as the stock rebounds from last week’s sharp tech-led selloff and tracks a broader risk-on move in growth...
🔴 Tempus AI, Inc. is trading 10.4% down today after reversing recent gains amid a broader tech selloff
Tempus AI, Inc. is trading at $46.84 (-10.38%) as it reverses sharply from the previous session's 10.00% gain amid a broader market downturn. • The move...
🔴 Tempus AI, Inc. is trading 6.6% down today as it gives back gains from recent rally
Tempus AI, Inc. is trading at $48.80 (down 6.6%) as the stock retreats from a sharp multi-day run-up amid a broader tech-led market selloff. • The stock is...
🟢 Tempus AI, Inc. surges 10.5% after launching a digital pathology consortium with Yale and Memorial Sloan Kettering
Tempus AI, Inc. (TEM) is trading 10.5% higher today, reaching $52.50, driven by a significant new strategic initiative. The rally follows the company's...
🟢 Tempus AI, Inc. is trading 9.6% up today on technical bounce after recent selloff
Tempus AI, Inc. is trading 9.6% up at $52.05, rebounding sharply after several days of heavy selling and profit-taking. • The move suggests a technical bounce...
🔴 Tempus AI, Inc. is trading 4.8% down today on profit-taking after pathology consortium launch
Tempus AI, Inc. is trading 4.8% down at $47.23 as investors take profits following the announcement of a new digital pathology open-source consortium. • The...
🔴 Tempus AI, Inc. is trading 4.6% down today despite announcing new digital pathology consortium with Yale and Memorial Sloan Kettering
Tempus AI, Inc. is trading 4.6% down at $47.33 today, a move that comes despite the company announcing a significant new initiative. • Tempus has launched a...
🔴 Tempus AI, Inc. is trading 5.5% down today on profit-taking following a sharp post-earnings rally
Tempus AI, Inc. is trading at $49.89, down 5.5% today as the stock pulls back from a significant rally fueled by strong Q1 results and bullish analyst...
🟢 Tempus AI, Inc. is trading 5.2% up today after Needham reiterates Buy rating and new cancer test launch
Tempus AI, Inc. is trading 5.2% up now at $53.08 following a positive analyst update and the introduction of a new oncology product. • Needham today...
Tempus AI to Launch xH Test, Finding 40% More Cancer Targets
Tempus AI will soon launch xH, its first whole-genome sequencing (WGS) assay for clinical use. The test identifies actionable cancer targets in blood and bone...
Tempus AI Unveils Next-Generation 'Lens' Platform to Accelerate Oncology Drug Development
Tempus AI has launched the next generation of its Lens platform, an agentic AI system designed to accelerate oncology drug development and research. This...
Tempus AI Launches 'Preview' to Speed Up Cancer Diagnostics
Tempus AI launched "Preview," an AI-powered application for precision oncology. The tool shortens the time between ordering diagnostic tests and receiving...
Tempus AI Outperforms Clinical Standards, Predicting Cancer Survival with New Model
Tempus AI (NASDAQ: TEM) announced initial results from its multimodal oncology foundation model at the 2026 American Society of Clinical Oncology (ASCO) Annual...
Tempus AI Expands 'Next' Platform for Real-Time Cancer Care Intelligence
Tempus AI expanded its AI-enabled 'Next' platform to deliver real-time clinical intelligence for oncology. The update introduces capabilities for six new...
Tempus AI Upgrades Tempus Hub With Agentic AI, Automating Oncology Workflows
Tempus AI integrated a next-generation agentic AI architecture into its Tempus Hub physician platform. The upgrade provides oncologists with an agent-first...
🟢 TEM surges 4.1% after announcing dozens of studies to be presented at major oncology conference
TEM is trading at $48.07 (+4.1%) after the company announced significant upcoming data presentations. • Tempus announced that 37 abstracts have been accepted...